Gatifloxacin 112811-59-3
160738-57-8
180200-66-2

inquire about Gatifloxacin
Gatifloxacin

Gatifloxacin sold under the brand names Gatiflo, Tequin and Zymar, is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar. In many countries, gatifloxacin is also available as tablets and in various aqueous solutions for intravenous therapy.

Side-effects and removal from the market

A Canadian study published in the New England Journal of Medicine in March 2006 claims Tequin can have "life threatening" side effects including serious diabetes. An editorial byDr. Jerry Gurwitz in the same issue called for the Food and Drug Administration (FDA) to consider giving Tequin a black box warning. This editorial followed distribution of a letter dated February 15 by Bristol-Myers Squibb to health care providers indicating action taken with the FDA to strengthen warnings for the medication. Subsequently it was reported on May 1, 2006 that Bristol-Myers Squibb would stop manufacture of Tequin, end sales of the drug after existing stockpiles were exhausted, and return all rights to Kyorin. Other serious side effects reported with gatifloxacin include hallucinations or liver damage.

Contraindications

Diabetes

Availability

Gatifloxacin is currently available only in the US and Canada as an ophthalmic solution. In India it is sold in tablet as well as in eye drop formulations.

read more [+]
Systematic (IUPAC) name: 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylicacid
Gatifloxacin CAS number: 112811-59-3
160738-57-8
180200-66-2
ATC code: J01MA16 S01AX21
PubChem: 5379
DrugBank: APRD00996
Formula: C19 H22 N3O4
Molecular mass: 375.394 g/mol
Gatifloxacin Assay/Purity: Typically NLT 98%
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.